As of 2025-02-16, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (6.58) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.13 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -408.8%.
The range of the Relative Valuation is (5.36) - (7.45) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
Range | Selected | |
Trailing P/E multiples | 18.3x - 39.0x | 28.8x |
Forward P/E multiples | 25.4x - 35.3x | 33.6x |
Fair Price | (5.36) - (7.45) | (6.58) |
Upside | -351.8% - -449.5% | -408.8% |
Date | P/E |
2025-02-14 | -10.10 |
2025-02-13 | -10.15 |
2025-02-12 | -10.01 |
2025-02-11 | -9.96 |
2025-02-10 | -9.96 |
2025-02-07 | -10.15 |
2025-02-06 | -10.25 |
2025-02-05 | -10.29 |
2025-02-04 | -10.15 |
2025-02-03 | -10.06 |
2025-01-31 | -10.63 |
2025-01-30 | -10.91 |
2025-01-29 | -10.91 |
2025-01-28 | -10.86 |
2025-01-27 | -10.91 |
2025-01-24 | -11.29 |
2025-01-23 | -11.34 |
2025-01-22 | -11.34 |
2025-01-21 | -11.24 |
2025-01-17 | -9.82 |
2025-01-16 | -9.16 |
2025-01-15 | -9.20 |
2025-01-14 | -8.97 |
2025-01-13 | -8.87 |
2025-01-10 | -8.30 |
2025-01-08 | -8.49 |
2025-01-07 | -8.82 |
2025-01-06 | -8.87 |
2025-01-03 | -9.11 |
2025-01-02 | -9.01 |
2024-12-31 | -9.01 |
2024-12-30 | -8.78 |
2024-12-27 | -9.25 |
2024-12-26 | -9.16 |
2024-12-24 | -8.82 |
2024-12-23 | -8.78 |
2024-12-20 | -8.68 |
2024-12-19 | -8.49 |
2024-12-18 | -8.35 |
2024-12-17 | -8.87 |
2024-12-16 | -8.73 |
2024-12-13 | -8.78 |
2024-12-12 | -8.63 |
2024-12-11 | -9.11 |
2024-12-10 | -9.39 |
2024-12-09 | -9.68 |
2024-12-06 | -9.72 |
2024-12-05 | -9.58 |
2024-12-04 | -9.63 |
2024-12-03 | -9.68 |